AbbVie ABBV Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $15B-9.7% | $16.62B+5.3% | $15.78B+2.3% | $15.42B+15.6% | $13.34B-11.6% | ||
| $4.22B-7.3% | $4.55B-14.2% | $5.3B+22.0% | $4.35B+8.6% | $4B-9.0% | ||
| $10.78B-10.6% | $12.07B+15.2% | $10.47B-5.5% | $11.08B+18.6% | $9.34B-12.7% | ||
| 71.9%-0.7pp | 72.6%+6.2pp | 66.4%-5.4pp | 71.8%+1.8pp | 70%-0.9pp | ||
| $3.58B-8.1% | $3.9B+9.1% | $3.57B+9.7% | $3.25B-1.2% | $3.29B-14.6% | ||
| $11.01B-8.8% | $12.07B-13.0% | $13.87B+31.8% | $10.53B+9.6% | $9.61B-42.1% | ||
| $3.99B-12.2% | $4.54B+139% | $1.9B-61.1% | $4.89B+31.1% | $3.73B— | ||
| 26.6%-0.7pp | 27.3%+15.3pp | 12.1%-19.7pp | 31.7%+3.8pp | 28%— | ||
| $1.04B-61.1% | $2.67B+274% | $714M-54.1% | $1.55B-6.4% | $1.66B— | ||
| $342M-59.9% | $853M+62.2% | $526M-14.2% | $613M+64.8% | $372M+117% | ||
| $695M-61.7% | $1.82B+876% | $186M-80.2% | $938M-27.1% | $1.29B+5,945% | ||
| 4.6%-6.3pp | 10.9%+9.7pp | 1.2%-4.9pp | 6.1%-3.6pp | 9.6%+9.8pp | ||
| $0.39-61.8% | $1.02+920% | $0.10-80.8% | $0.52-27.8% | $0.72+3,700% | ||
| $5.93B-9.3% | $6.53B+63.4% | $4B-42.8% | $6.98B+20.9% | $5.77B— | ||
| 39.5%+0.2pp | 39.3%+14.0pp | 25.3%-19.9pp | 45.3%+2.0pp | 43.3%— | ||
| $3.99B-12.2% | $4.54B+139% | $1.9B-61.1% | $4.89B+31.1% | $3.73B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AbbVie's revenue?
- AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
- Is AbbVie profitable?
- AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
- What are AbbVie's profit margins?
- Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
- What is AbbVie's earnings per share?
- AbbVie's diluted EPS over the trailing twelve months is $2.03.
- Where does AbbVie's income statement data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
